• Oral formulations of 5-aminosalicylic acid: first-line medications to induce and maintain remission
• Conventional corticosteroids: given to patients who do not respond to 5-ASA formulations within 10 to 14 days
• Azathioprine and 6-mercaptopurine: American Gastroenterological Association and American College of Gastroenterology guidelines suggest AZA or 6-mercaptopurine for patients with severe flares of UC
• Cyclosporine: intravenous cyclosporine A is a second-line therapy for patients with severe and corticosteroid-refractory UC
• Anit-TNF antibodies: infliximab, adalimumab and golimumab
More Articles on Gastroenterology:
6 Things to Know About Ulcerative Colitis, Crohn’s Disease & Cancer Risk
3 Things to Know About Celiac Disease Screening
Dr. Michael Uzer Joins Sarah Bush Lincoln Health Center
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
